Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. - Varghese AM; Perry MA; Chou JF; Nandakumar S; Muldoon D; Erakky A; Zucker A; Fong C; Mehine M; Nguyen B; Basturk O; Balogun F; et al. (Nature medicine, 2025)